Home
CLYM
CLYM News

Latest CLIMB BIO INC (CLYM) News on May 10, 2025

Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX, ACB

PR Newswire

a day ago

Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX, ACB

Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX

Exec Edge

a month ago

Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

GlobeNewswire

a month ago

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference

GlobeNewswire

a month ago

Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference

Climb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Quarterly Update Report

Exec Edge

a month ago

Climb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Quarterly Update Report

Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates

GlobeNewswire

a month ago

Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates

Climb Bio: Meet The Newest Star in Autoimmune Disease Treatment – Initiation Report

Exec Edge

2 months ago

Climb Bio: Meet The Newest Star in Autoimmune Disease Treatment – Initiation Report

Climb Bio to Present at Upcoming Investor Conferences

GlobeNewswire

2 months ago

Climb Bio to Present at Upcoming Investor Conferences

Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer

GlobeNewswire

3 months ago

Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer

Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

GlobeNewswire

3 months ago

Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy

GlobeNewswire

4 months ago

Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy

Climb Bio to be Added to the Nasdaq Biotechnology Index

GlobeNewswire

5 months ago

Climb Bio to be Added to the Nasdaq Biotechnology Index

Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

GlobeNewswire

6 months ago

Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board

GlobeNewswire

6 months ago

Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board

Climb Bio to Present at Upcoming Investor Conferences

GlobeNewswire

6 months ago

Climb Bio to Present at Upcoming Investor Conferences

Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event

GlobeNewswire

7 months ago

Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event

Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024

GlobeNewswire

7 months ago

Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024

Climb Bio to Present at William Blair’s Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19

GlobeNewswire

7 months ago

Climb Bio to Present at William Blair’s Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19

Share on Social Networks: